跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2022/06/043078
CTRI/2022/06/043078尚未招募不适用

Single dose, randomization blinded, two-period, two-treatment, twosequence,crossover, oral bioequivalence study of Mylan’s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford,Middlesex, TW8 9GS, UK, in Healthy adult male and female (not of childbearing potential) human volunteers under fed conditions.

Mylan Laboratories Limited1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年8月6日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
60
试验地点
1
主要终点
The objective of this study is to investigate the comparative relative oral bioavailability of
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

 Protocol Title Single dose, randomization blinded, two-period, two-treatment, twosequence, crossover, oral bioequivalence study of Mylan’s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford,Middlesex, TW8 9GS, UK, in Healthy adult male and female (not of childbearing potential) human volunteers under fed conditions.
 Protocol No. ABDL-TBP-1003
 Product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg
 Study Type Pivotal Fed Bioequivalence
 Version 00         Region of Submission          PEPFAR
 Protocol Date 20 Jan 2022         Revision Date    :                  N/A
 General Description This protocol describes a single-dose, randomization blinded, two-period, two-treatment, two-sequence, crossover study to investigate the bioequivalence of Mylan’s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK. Pharmacokinetics will be characterized in Sixty (60) healthy, adult male and female (not of childbearing potential) human volunteers following administration of a Single oral dose of either test product or reference product administration under fed conditions. 28 blood samples of six milliliter (1 × 6 mL) each will be collected in K3 EDTA tubes at pre-dose (0.00) and the following times after dosing: 0.084, 0.17, 0.25, 0.333, 0.5, 0.67, 0.83, 1.0, 1.25, 1.50, 1.75, 2.0, 2.25, 2.50, 2.75, 3.0, 3.50, 4.0, 5.0, 6.0, 8.0, 10, 12, 24, 36, 48 and 72 hours. The collected blood samples will be cooled in an ice bath and centrifuged under refrigeration as soon as possible. Two aliquots of plasma will be extracted and stored in suitably labeled tubes at -70°C or colder with an acceptable operating range within -55°C to -85°C at the clinical site until transferred on dry ice to analytical site. For the determination of the pharmacokinetic disposition of the formulations, there will be a total of 56 blood samples involving a total of 336 mL of blood collected for pharmacokinetic analysis from each subject provided they complete all blood collections in the study. There will be at least 07 days between dosing times for the treatment periods. The bioequivalence of Mylan’s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK will be assessed by a statistical comparison of various pharmacokinetic parameters derived from the plasma concentration-time curves of the drug.
 OBJECTIVESPrimary Objective: The objective of this study is to investigate the comparative relative oral bioavailability of Mylan’s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK, following a single oral dose of test product or reference products administration under fed conditions. Secondary Objective: To monitor the adverse events and to ensure the safety of the subjects.
 STUDY DRUGInvestigational Drug: Test Product (T): Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg. Manufactured By: Mylan Laboratories Limited., India Reference Product (R): Trimeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured by: GlaxoSmithKline Research & Development Limited, Glaxo Operations UK Ltd, Priory Street, Ware, Hertfordshire, SG12 0DG, UK Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK Product Description: GSK1349572 5mg/Abacavir 60mg/Lamivudine 30mg pediatric dispersible tablets are pale yellow, biconvex, oval, film-coated, debossed with ‘SV WTU’ on one side and plain on the opposite side. Each tablet contains 70.2 mg abacavir sulfate, which is equivalent to 60 mg of abacavir free base; 5.26 mg dolutegravir sodium, which is equivalent to 5 mg of dolutegravir free acid; and 30 mg of lamivudine. The tablets are packaged in HDPE bottles with child-resistant closures that include an induction seal and a desiccant. Store and dispense in the original package, protect from moisture, and keep bottles tightly closed. Do not remove desiccant. In the study site pharmacy, store up to 30°C (86°F). The label on each subject’s dispensed drug(s) will include the study code identifier and the randomization number (i.e., subject number). Additional information such as dosing period, route of administration and date, may be appropriate for inclusion on the dispensed drug’s label. The label should include sufficient information to ensure compliance with applicable local/regional regulations and the protocol. An example of an acceptable label would contain the following: study number, period, subject number, generic drug name, dosage form, route of administration, quantity, clinical site information, and text: for clinical use only.
 STUDY CONDUCT This is a single-dose, randomization blinded, two-period, two-treatment two-sequence crossover study investigating the bioequivalence of Mylan’s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK, in healthy adult male and female (not of childbearing potential) human volunteers following a single oral dose of test product or reference product in Sixty (60) healthy adult human volunteers under fed conditions. Subjects will be housed 11.00 hours prior to drug dosing of each period and until at least 72.00 hours after investigational drug administration. Blood samples will be collected prior to dosing and 72.00 hours after each dosing. There will be at least 07 days between dosing times for the treatment periods. Individual subjects should be dosed at approximately the same time of day in each dosing period. It is the sponsor’s intent to complete all subjects simultaneously. Thus, it is anticipated that all subjects will be completed in a single cohort within approximately 12 days following the initiation of dosing. If multiple cohorts are necessary to enroll the required number of subjects, no two cohorts can be dosed on the same day.
 Screening Procedures Each prospective subject must agree to participate in screening procedures by signing the most recent Institutional Review Board/Independent Ethics Committee approved Informed Consent Form (ICF) before any screening procedure is initiated. Each subject will undergo a screening procedure for health assessment, which consists of a complete medical history, physical examination with vital signs, clinical laboratory evaluations, 12-lead ECG and Chest X-ray PA view. The Principal Investigator or Medical Sub-Investigator will review the inclusion and exclusion criteria to confirm eligibility of each subject prior to enrollment. Modified Patient Health Questionnaire (PHQ) -12 questionnaires will be evaluated before period-1 check in (Appendix XII). The physician in charge will assess abnormal values to determine if it is clinically significant. Clinical/Laboratory Diagnostic Tests: 1. Hematology: Red blood cell count, White blood cell count, Differential white blood cell count (Neutrophils%, Lymphocytes%, Eosinophils%, Monocytes % and Basophils %), Hemoglobin estimation, Platelet count, Blood grouping and Rh typing 2. Biochemistry: Serum creatinine, Blood urea, SGOT (AST), SGPT (ALT), Serum alkaline phosphatase (ALP), Total bilirubin, Blood sugar/ Plasma Glucose (Random), Serum electrolytes (Sodium, Potassium and Chloride) 3. Serology: HIV (1 & 2) antibodies, Hbs Ag (Hepatitis B surface antigen), HCV antibodies and VDRL/Syphilis. 4. Urine analysis: Color, Appearance/Transparency, pH, Specific gravity, Glucose, Ketones, Bilirubin, Blood, Leucocytes, Proteins, Nitrite, Urobilinogen and Urine microscopic examination (Pus Cells, Red Blood Cells, Epithelial Cells, Casts and Crystals). 5. Additional Tests: Creatinine Clearance (by using Cockroft-Gault method), HLA-B 5701 allele test, Prothrombin Time (PT) and INR. Serum pregnancy test (for women volunteers).
 Housing Enough subjects from the general population will be available in the clinic for Period 1 dosing in order to dose the required number of subjects. Subjects will be housed 11.00 hours prior to and until at least 72.00 hours after dosing in each period of the study.
 Toxicity Management In the event of a discontinuation of dolutegravir (DTG) containing product for suspected drug induced liver injury, other clinically significant liver chemistry elevations, severe skin reaction or hypersensitivity reaction, subjects should not be rechallenged with a dolutegravir-containing product due to the risk of a recurrent reaction. These subjects should be withdrawn from study. Further details on this are provided in this section as appropriate. All toxicity related adverse events and gradings will be documented as per the standards mentioned in the information Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Refer Section 11 Sr.No 12
 Bioanalytical Method A validated assay method will be employed for the analysis of Abacavir/ Dolutegravir/ Lamivudine in plasma samples. Full validation of the method, including precision, accuracy and reproducibility will be included in the final report, along with a statement regarding the stability of frozen samples.
 Pharmacokinetic Parameter Determination Concentration data of subject versus time, which are received after analysis of samples, will be included in the final data analysis. Subjects who complete all periods of the study will be considered for the pharmacokinetic and statistical analysis. Concentration data of subjects who withdrawn from the study due to adverse events will be reported separately and will not be included in the pharmacokinetic and statistical analysis. Data from subjects with missing concentration values (missed blood samples, lost samples, samples unable to be quantified) may be used if pharmacokinetic parameters can be estimated using remaining data points on case to case basis, otherwise data from these subjects will be excluded from the final analysis. All concentration values below the limit of quantification (BLOQ/BLQ) will be set to zero for all pharmacokinetic and statistical calculations. Any missing samples will be reported as ‘M’ and will not be included for pharmacokinetic and statistical analysis. The following pharmacokinetic parameters will be computed using validated statistical software for Abacavir / Dolutegravir / Lamivudine. Cmax                    :           Maximum observed plasma concentration following each treatment. AUC0-t                 :          AUC is defined as the area under the concentration-time curve. AUC will be estimated using the                                        Linear Up Log Down calculation method i.e. linear trapezoidal for pre-Cmax and log trapezoidal post Cmax. AUC0-inf              :          The area under the plasma concentration versus time curve from time zero to infinity.                                         Where AUC0-inf = AUC0-t + Ct/ λz, Ct is the last measurable concentration and λz is the terminal                                         elimination rate constant. AUC_%Extr ap_ obs:      The residual area in percentage will be determined by the formula, [(AUC0-inf - AUC0-t)/AUC0-inf] x 100. Tmax                     :         Time of the maximum measured plasma concentration t½                          :         The elimination half-life will be calculated as 0.693/ λz Kel                         :          First order rate constant associated with the terminal (log-linear) portion of the curve. This is estimated                                          via linear regression of time vs. log concentration.This parameter will be calculated by linear least                                          squares regression analysis using at least last three or more non-zero plasma concentration values. Note: 1. For all the above computations, actual time points of the sample collection will be used in case of sample collection deviations. 2. For an acceptable Kel value, r should not be less than 0.8944 (or r2 not less than 0.80). If r is less than 0.8944, then Kel is set missing. Rarely, under certain special situations, other rules may be used. In these instances (ex. When low % of Kel able to be determined), the statistical programmer or statistician will consult with pharmacokinetics. Any alternative rules used must be documented in a memo to the Trial Master File (TMF). 3. If the pre-dose value is greater than 5% of Cmax, that subject will be dropped from pharmacokinetics and statistical analysis. 4. For any subject having very low plasma concentrations, if its AUC is less than 5% of reference product geometric mean AUC (which should be calculated without inclusion of data from the outlying subject). 5. If any subject experiences emesis at or within two times the median Tmax time following the drug administration in each study period, such subject data will be analysed however data of the subject will not be included in pharmacokinetic and statistical analysis.
 Statistical Analysis of the Pharmacokinetic Parameters Statistical analysis will be performed on the data obtained from the subjects who complete all periods of the study as per IEC approved protocol using appropriate validated statistical software. Descriptive statistics of all the pharmacokinetic parameters will be computed and reported for Abacavir/ Dolutegravir/ Lamivudine. The summary statistics (for relevant pharmacokinetic parameters) will be computed and reported for both test and reference products of Abacavir/ Dolutegravir/ Lamivudine. The ln-transformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-inf of Abacavir/ Dolutegravir/ Lamivudine will be subjected to Analysis of Variance (ANOVA). ANOVA model will include Sequence, Formulation, Period and Subject (Sequence) as as fixed effects. Sequence effect will be tested using Subject (Sequence) as error term. An F-test will be performed to determine the statistical significance of the effects involved in the model at a significance level of 5% (alpha =0.05). All the period, Treatment and sequence effects will be tested at 5% Level of Significance. Two one-sided test for bioequivalence and 90 % confidence intervals for the ratio of least squares mean between drug formulations will be calculated, for ln-transformed data of Cmax, AUC0-t and AUC0-inf of Abacavir / Dolutegravir / Lamivudine. The power of a test to detect 20% difference between test and reference products will be computed and reported for Abacavir / Dolutegravir / Lamivudine. Ratio of least squares means of test and reference products will be computed for ln-transformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-inf. Ratio analysis will be reported for ln-transformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-inf of Abacavir / Dolutegravir / Lamivudine. Intra-Subject variability will be computed for ln-transformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-inf of Abacavir / Dolutegravir / Lamivudine. Bioequivalence of the test product with that of the reference product under fed conditions will be concluded if the 90% confidence intervals of geometric least square mean ratio of the test and reference product falls within the acceptance range of 80.00 % – 125.00% for lntransformed pharmacokinetic parameters of Cmax, AUC0-t and AUC0-inf for Abacavir / Dolutegravir / Lamivudine reported on normal scale. It is the sponsor’s intent to complete this study in one cohort. In the event that separate enrollments are necessary to complete the intended number of subjects, appropriate adjustments may be made to the statistical model to reflect the multi-cohort nature of the study. a. Additional cohorts will be recruited and dosed under the following conditions: i. Recruiting for additional enrollment(s) begin before the end of the final period of the previous enrollment; ii. Subjects are recruited from the same population, under the same protocol requirements; iii. dosing of additional cohorts began as soon as practical after their recruitment; and iv. no two cohorts are dosed on the same day. b. Appropriate adjustments will be made to the statistical model to reflect the multi-cohort nature of the study if: i. the number of cohorts is less than or equal to 3; and ii. there are at least 6 subjects in each cohort.
 APPENDIX VI: STUDY CONDUCT INFORMATION The clinical research organization conducting this study on behalf of Mylan Laboratories Ltd., India is required to complete this sheet and forward to Mylan prior to the enrollment of any subjects into the study. Any updates throughout the study conduct period must be reported on this sheet. Protocol Number: ABDL-TBP-1003 Protocol Title: Single dose, randomization blinded, two-period, two-treatment, two-sequence, crossover, oral bioequivalence study of Mylan’s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK, in Healthy adult male and female (not of childbearing potential) human volunteers under fed conditions.
 Principal Investigator                                  :       Dr. Anjum Jabeen, M.B.B.S., M.D., (please attach curriculum vitae when return to Mylan)      
 Address of Principal Investigator                       M/s. Aizant Drug Research Solutions Private Limited                                                                             Clinical Pharmacology Unit-II                                                                             St. Theresa’s Hospital,                                                                             Clinical Pharmacology Department, 02nd Floor,                                                                             Premises No.7-1-645/A, Sanathnagar, Hyderabad                                                                             Telangana, India– 500018 Phone Number of Principal Investigator             + 91 40 23811981, 91 40 23811982
 Clinical Research Facility                              :   Clinical Pharmacology Department,  Address of Clinical Facility                                 M/s. Aizant Drug Research Solutions Private Limited                                                                             Clinical Pharmacology Unit-II                                                                             St. Theresa’s Hospital,                                                                             Clinical Pharmacology Department, 02nd Floor,                                                                             Premises No.7-1-645/A, Sanathnagar, Hyderabad                                                                             Telangana, India– 500018.                                                                             Phone No: + 91 40 23811981, 91 40 23811982
 Stastical Investigator                                  :      Mr. Uday Kumar Konda M.Sc.,M. Phil                                                                            Pharmacokinetic & Statistical analysis                                                                            Aizant Drug Research Solutions Pvt. Ltd.,                                                                            Survey No: 172 &173, Apparel Park Road,                                                                             Dulapally Village, Dundigal Gandimaisamma Mandal, Medchal-                                                                             Malkhajgiri District - 500100, Telangana, India. Phone No: +91 40                                                                             23792190/91/92, Fax No: +91 40 23792223 Bioanalytical Investigator                             :      Mr. Amarnath Jaiswal, M Sc. (Tech.),                                                                             Mylan Laboratories Limited, Clinical Research Centre,                                                                             Saradhi Chambers, Plot No: A-4,                                                                             Beside Poulomi Hospital, Rukminipuri, Dr. A. S. Rao Nagar,                                                                             Hyderabad, India – 500062.                                                                             Phone No: +91 40 30492901 Fax No: +91 40 27138562
 Listing of Sub-Investigator(s)                     :        Dr. K. Suraj Kumar, M.B.B.S., (attach separate sheet, if necessary) Institutional Review Board                          :          Maarg Independent Ethics Committee

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded

入排标准

年龄范围
18.00 Year(s) 至 45.00 Year(s)（—）
性别
All

入选标准

  • •Subjects must fulfill all of the following criteria to be considered for inclusion into this study:
  • •Normal healthy adult male and female (not of childbearing potential) human subjects, age between 18 to 45 years (inclusive of both).
  • •A female may be eligible to enter and participate in the study if she is of non-childbearing potential, defined as either post-menopausal (12 months of spontaneous amenorrhea and equal to or older than 45 years of age) or physically incapable of becoming pregnant documented tubal ligation, hysteroctomy or bilateral oophorectomy.
  • •Body mass index of ≥ 18.5 kg/m2 and ≤ 24.9 kg/m2 and weight ≥ 50.00 kg.
  • •Healthy according to the laboratory results and physical examination, performed within 21 days prior to the commencement of the dosing in Period-
  • •Subject whose clinical laboratory values are within normal limits or clinically insignificant as determined by physician or principal investigator to be of no clinical significance.
  • •HLA-B 5701 allele negative subjects.
  • •Have normal ECG, Chest X-ray and vital signs.
  • •Non-smoker and Non-alcoholic.
  • •Subject able to communicate effectively and willing to provide informed consent.
  • •Subject willing to adhere to protocol requirements as evidenced by informed consent approved by an Independent Ethics Committee (IEC).

排除标准

  • •A subject will not be eligible for study participation if he/she meets any of the following criteria:
  • •2.Positive test result for or HIV-1 antibody or HIV Type 2 (HIV-2) antibody (HIV Ab) or VDRL / syphilis.
  • •Positive hepatitis B surface antigen (HBs Ag) and hepatitis C virus antibody (HCV Ab) test results at screening or within 03 months prior to starting the study intervention are excluded from the study.
  • •Any history or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, dermatological, neurological, psychiatric diseases or disorders and Clinically significant abnormal values of laboratory parameters.
  • •Subjects with moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification.
  • •Subject has creatinine clearance of <60 mL/min
  • •Subject having Modified Patient Health Questionnaire (PHQ)-12 questionnaires >
  • •Any history of bleeding disorders, peptic ulcer diseases, hemorrhoids, wounds/ ulcers.
  • •History or presence of drug abuse in the past one year.
  • •Difficulty in swallowing tablets/capsules.
  • •Any history of difficulty in donating blood.
  • •Resting Blood pressure is < 110/70 and > 129/79 millimeters of mercury (Systolic blood pressure/ Diastolic blood pressure).
  • •Usage of any prescribed medication during last 14 days and for OTC medicinal products, herbal products during the last 07 days preceding the first dosing.
  • •Usage of any clinically significant medications last 30 days preceding the first dosing.
  • •Any clinically significant illness during 3 months before screening.
  • •15.Participation in a drug research study/donation of blood within past 90 days.
  • •ALT > 1.5 xULN or total bilirubin > 1.5 xULN.
  • •Consideration by the investigator, for any reason that the subject is an unsuitable candidate to receive study drug.
  • •Breastfeeding
  • •Clinically significant history of psychiatric disease.
  • •Subject positive for alcohol test (by using urine/ blood), urine screen for drugs of abuse [Cannabinoids (Marijuana / Tetra Hydro Cannabinoids-THC), Cocaine, Opiates (morphine), Amphetamine, Barbiturates and Benzodiazepines] and pregnancy test (for female subjects only) at the time of each period check-in will be excluded from the study.

结局指标

主要结局

The objective of this study is to investigate the comparative relative oral bioavailability of

时间窗: The objective of this study is to investigate the comparative relative oral bioavailability of | Mylan’s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension | 60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK, following a single oral dose of test product or reference products administration under fed conditions.

60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK, following a single oral dose of test product or reference products administration under fed conditions.

时间窗: The objective of this study is to investigate the comparative relative oral bioavailability of | Mylan’s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension | 60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK, following a single oral dose of test product or reference products administration under fed conditions.

Mylan’s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension

时间窗: The objective of this study is to investigate the comparative relative oral bioavailability of | Mylan’s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension | 60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK, following a single oral dose of test product or reference products administration under fed conditions.

次要结局

  • To monitor the adverse events and to ensure the safety of the subjects.(45 days clinical schedule)

研究者

申办方类型
Pharmaceutical industry-Global

研究点 (1)

Loading locations...

相似试验

Unknown
不适用
Comparative pharmacokinetic and Pharmacodynamic trial of Wosulin R Insulin Injection (in comparision with Human Actrapid HM penfil insulin injection) in healthy human adult volunteers
CTRI/2015/05/005801Wockhardt Ltd India48
已完成
1 期
Comparative bioequivalence study of a generic formulation of fingolimod capsule against the innovator fingolimod capsule in fasting healthy subjects
ACTRN12615001055594Zenith Technology Corporation Limited24
尚未招募
不适用
Bioequivalence study of Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg (fasting)
CTRI/2022/06/043058Mylan Laboratories Limited
尚未招募
不适用
Bioequivalence study of Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg in Healthy adult male and female (not of childbearing potential) human volunteers under fed conditions
CTRI/2022/06/043078Mylan Laboratories Limited
尚未招募
不适用
bioequivalence study of Abacavir / Dolutegravir / Lamivudine (60 mg / 5 mg / 30 mg) Dispersible Tablets in Healthy adult male and female (not of childbearing potential) human volunteers under fed conditions.
CTRI/2021/04/033145Mylan Laboratories Limited